fda approved weight loss glp-1 approves Foundayo, an oral alternative to Wegovy and Ozempic FDA approves new GLP-1 weight

First, it is difficult for GLP-1 agonists to achieve anti-fibrosis effects because the major effect of GLP-1 agonists on MASH is likely to be indirect by extrahepatic path

The military and biotech presence grounds the market in evidence-based approaches

In the Phase 2 NEJM trial (2023), participants on 12 mg lost an average of 24.2% of body weight at 48 weeks

PMID: 25177371

Research Background & Mechanistic Focus Current research use centers on single-pathway incretin receptor signaling and comparative peptide-pathway models, comparative presentation or formulation behavior where applicable, and controlled experimental models designed to evaluate compound-specific signaling activity within non-clinical laboratory systems